Savicol (valproic acid) / Valerio Therap - LARVOL DELTA

A TUMOR WITH AN IDENTITY CRISIS: DECODING CDX2-POSITIVE LUNG CANCER (CHEST 2025) - "This case underscores the diagnostic complexity of lung adenocarcinoma and the challenge of differentiating PEAC from MCRC. While CDX2 remains a highly specific marker for intestinal malignancies, its presence in lung adenocarcinomas necessitates a cautious, multidisciplinary approach. Comprehensive histopathologic evaluation, immunohistochemistry, and molecular profiling are essential for guiding treatment decisions and optimizing patient care."

Colorectal Adenocarcinoma • Colorectal Cancer • Diabetes • Gastrointestinal Cancer • Hypertension • Lung Adenocarcinoma • Lung Cancer • Metabolic Disorders • Non Small Cell Lung Cancer • Oncology • Palliative care • Pulmonary Disease • Respiratory Diseases • Solid Tumor • APC • BRAF • CDX2 • HER-2 • KRAS • NKX2-1 • NRAS

LUNG CANCER IN DISGUISE: A CASE OF PULMONARY ENTERIC ADENOCARCINOMA (PEAC) MASQUERADING AS METASTATIC COLORECTAL CARCINOMA (CHEST 2025) - "Pulmonary enteric adenocarcinoma (PEAC) is a rare NSCLC subtype recognized by WHO, histologically mimicking metastatic colorectal cancer, arising from overlapping pulmonary and colonic mucosal cells."

Clinical • IO biomarker • Metastases • Atrial Fibrillation • Colorectal Cancer • Gastric Cancer • Genetic Disorders • Large Cell Carcinoma • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Respiratory Diseases • Septic Shock • Skin Cancer • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma • CDX2 • CLDN4 • NKX2-1 • PD-L1 • SMARCA4 • STK11

Primary pulmonary enteric adenocarcinoma in a young adult: a diagnostic and therapeutic challenge. (PubMed, BMJ Case Rep) - "These findings revealed the diagnosis of PEAC.She underwent 6 cycles of cisplatin and pemetrexed chemotherapy with tolerable toxicity and a partial metabolic response on follow-up PET-CT. This case underscores the importance of a multimodal approach to differentiate PEAC from metastatic colorectal cancer and facilitate appropriate treatment."

Journal • Back Pain • Colorectal Cancer • Fatigue • Lumbar Back Pain • Lung Adenocarcinoma • Lung Cancer • Musculoskeletal Pain • Non Small Cell Lung Cancer • Oncology • Pain • Solid Tumor • CDX2 • Napsin A • NKX2-1

Case Report: Controversies in managing pulmonary enteric adenocarcinoma: reflections from an early-stage case. (PubMed, Front Oncol) - "Furthermore, the patient's favorable outcome following R0 resection without adjuvant therapy reinforces surgical intervention as the cornerstone of treatment for localized PEAC, particularly in early-stage disease. Advanced cases require early multidisciplinary collaboration to develop individualized treatment."

Journal • Colorectal Adenocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CDX2 • HER-2

The clinicopathologic characteristics and tumor immune microenvironment of pulmonary enteric adenocarcinoma. (PubMed, Ann Med) - "In this study, PEAC patients showed low CD8+ T cell, CD45RO+ T cell and LAG-3 expression, and negative PD-L1 expression. And all patients were MMS."

Biomarker • IO biomarker • Journal • Retrospective data • Colorectal Adenocarcinoma • Colorectal Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD8 • CDX2 • LAG3 • NKX2-1 • PD-L1

Double the trouble: pulmonary enteric adenocarcinoma with synchronous contralateral pulmonary adenocarcinoma. (PubMed, Oxf Med Case Reports) - "We describe plausible mechanisms by which two distinct pulmonary malignancies are present in the contralateral lobes. To the best of our knowledge, this is the first reported case of synchronous invasive pulmonary adenocarcinoma and PEAC."

Journal • Colorectal Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Pulmonary Enteric Adenocarcinoma in a Super-Elderly Patient: A Case Report and Literature Review. (PubMed, Respirol Case Rep) - "At the one-year postoperative follow-up, he remained disease-free. This case emphasises the diagnostic utility of immunohistochemistry and the feasibility of surgical management, even in super-elderly patients with PEAC."

Journal • Colorectal Adenocarcinoma • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CDX2 • NKX2-1

Pulmonary enteric adenocarcinoma with progression disease after second - line therapy: a case report. (PubMed, Front Oncol) - "Then the second-line XELOX regimen (oxaliplatin combined with capecitabine) was adjusted...Anlotinib targeted drugs were selected for third-line treatment, but considering the overall poor condition of the patient, the patient himself refused further treatment. Finally, after discharge, the patient went to the local hospital for nutritional support and symptomatic treatment. The results suggest that standard first-line therapies (immunotherapy plus chemotherapy) and colorectal cancer regimens may have a relatively limited impact on survival in KRAS-driver positive advanced PEAC."

IO biomarker • Journal • Colorectal Adenocarcinoma • Colorectal Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS • PD-L1

Case report: 18F-FDG PET/CT in pulmonary enteric adenocarcinoma. (PubMed, Front Oncol) - "This case report expands the radiological spectrum of PEAC, adds to the limited literature, and emphasizes the role of 18F-FDG PET/CT in diagnosing such diseases. It also underscores the importance of a multidisciplinary approach in the management of PEAC."

FDG PET • Journal • Colorectal Adenocarcinoma • Colorectal Cancer • Cough • Gastrointestinal Cancer • Gastrointestinal Disorder • Infectious Disease • Lung Cancer • Oncology • Pneumonia • Respiratory Diseases • Solid Tumor

Gefitinib, an effective treatment option for patients with pulmonary enteric adenocarcinoma harboring compound EGFR L858R and A871G mutation. (PubMed, Invest New Drugs) - "Following surgery, the patient underwent treatment with the first-generation EGFR-TKI, gefitinib, and achieved an impressive 5-year progression-free survival (PFS). This suggests that gefitinib may serve as an effective treatment option for PEAC patients with EGFR L858R + A871G compound mutations."

Journal • Colorectal Adenocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

DOUBLE THE TROUBLE: PULMONARY ENTERIC ADENOCARCINOMA WITH SYNCHRONOUS CONTRALATERAL LOBE PULMONARY ADENOCARCINOMA (CHEST 2023) - "The patient received palliative intent chemotherapy with carboplatin, pemetrexed, and pembrolizumab which led to complete response of the right lobe PEAC and partial response of the left lobe adenocarcinoma. Pulmonary enteric adenocarcinoma is a challenging diagnosis, with morphologic and immunohistochemical features that are nearly indistinguishable from colorectal carcinoma. CK7 immunoreactivity may assist in differentiating PEAC from metastatic gastrointestinal cancer. Combination chemotherapy with platinum-based chemotherapy and immune checkpoint inhibitors may be effective in treating pulmonary enteric adenocarcinoma, particularly if there is a greater tumor mutational burden."

IO biomarker • Tumor mutational burden • Colorectal Adenocarcinoma • Colorectal Cancer • Cough • Gastrointestinal Cancer • Gastrointestinal Disorder • Lung Adenocarcinoma • Lung Cancer • Oncology • Pulmonary Disease • Respiratory Diseases • Sarcoma • Solid Tumor • CDKN2A • CDKN2B • EGFR • KRAS • Napsin A • NKX2-1 • NOTCH1 • PD-L1 • TMB • TP53 • TP63

Clinical presentation and outcome of patients with enteric-type adenocarcinoma of the lung: A pooled analysis of published cases. (PubMed, Lung Cancer) - "Enteric-type adenocarcinoma of the lung (lung-ETAC, former pulmonary enteric adenocarcinoma, PEAC) is a rare subtype of non-small cell lung cancer (NSCLC), which shares morphological and immunohistochemical features with lung and colorectal adenocarcinoma...In conclusion, advanced lung-ETAC patients appeared to have a better prognosis compared to other subtypes of NSCLC. Moreover, the mutational rate and microsatellite instability found in lung-ETACs suggest that a significant proportion of these patients could benefit from target therapies and immunotherapy."

IO biomarker • Journal • Retrospective data • Review • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Lung Adenocarcinoma • Lung Cancer • Microsatellite Instability • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • BRAF • EGFR • KRAS • MSI • NRAS • ROS1

Newly Detected Solitary Lung Enteric Adenocarcinoma in Patients Diagnosed with pT1pN0 Colorectal Carcinoma: Are They Metastatic or Metachronous Primary Pulmonary Enteric Adenocarcinoma? (USCAP 2023) - "Solitary lung metastases in pT1pN0 CRC are extremely rare. These patients should undergo a long time follow-up because recurrences can arise even a long time after the initial diagnosis. It is important to further identify risk factors associated with distant metastases to adapt the therapeutic management of these patients."

Clinical • Metastases • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Adenocarcinoma • Oncology • Solid Tumor • CDX-2 • KRAS • NKX2-1

Genomic and epigenomic profiles distinguish pulmonary enteric adenocarcinoma from lung metastatic colorectal cancer. (PubMed, EBioMedicine) - "These results provide solid evidence of PEAC-specific genomic characteristics and demonstrate the potential utility of DNA methylation markers for auxiliary diagnosis of PEAC and lmCRC."

Journal • Colorectal Cancer • Gastrointestinal Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • APC • EGFR • HER-2 • KRAS

Progress in pulmonary enteric adenocarcinoma (PubMed, Zhonghua Zhong Liu Za Zhi) - "Pulmonary enteric adenocarcinoma (PEAC), as a rare histologic subtype of primary lung adenocarcinoma, is defined as an adenocarcinoma in which the enteric component exceeds 50%...In terms of treatment, conventional non-small cell lung cancer (NSCLC) regimens rather than colorectal cancer regimens are now recommended. There is still an urgent need for more basic and clinical research, in-depth exploration of its molecular feature and pathogenesis from the level of omics and other aspects, to help diagnosis and differential diagnosis, and find the optimal chemotherapy regimen, possibly effective targeted therapy and even immunotherapy."

IO biomarker • Journal • Colorectal Cancer • Gastrointestinal Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CDX-2 • KRAS • NKX2-1

Genetic mutation profiles and immune microenvironment analysis of pulmonary enteric adenocarcinoma. (PubMed, Diagn Pathol) - "This study demonstrated that PEAC was characterized by low-frequency RTK gene mutation, high KRAS mutation, low PD-L1 expression, low TMB, and low CD8+ T cells infiltration."

IO biomarker • Journal • Colorectal Cancer • Gastrointestinal Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD68 • CD8 • KRAS • PD-L1 • TMB • TP53

Primary Enteric Adenocarcinoma Lung with Mesenchymal Epithelial Transition Factor Amplification: A Case Report. (PubMed, Gulf J Oncolog) - "This is a rare case of PEAC with c-MET over expression. The MET axis that is implicated in pathogenesis of colonic adenocarcinomas might also be the molecular pathway for the development of PEAC."

Clinical • Journal • Colorectal Adenocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pain • Respiratory Diseases • Solid Tumor • ALK • CDX-2 • EGFR • NKX2-1 • ROS1

Pulmonary enteric adenocarcinoma. (PubMed, Transl Oncol) - "As for immunohistochemistry (IHC), CDX-2, villin, and CK7 are significantly positive in PEAC. This review focuses on the pathologic features, immunohistochemical examination, mutation analysis, diagnosis, treatment, and prognosis of PEAC."

Journal • Review • Colorectal Adenocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CDX-2 • HER-2 • KRAS